Tuberculosis vaccines

Vaccines

Volumn , Issue , 2008, Pages 857-885

  Smith, Kim Connelly ^a,b   Orme, Ian M ^c   Starke, Jeffrey R ^d  

^a MEMORIAL HERMANN HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158943284     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50037-4     Document Type: Chapter

References (432)

1. JR Starke (1991) Bacille Calmette-Guérin vaccine. Semin Pediatr Infect Dis 2 153-158.
2. L Lugosi (1992) Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology: a review. Tuber Lung Dis 73 252-261.
3. C Dye (2006) Global epidemiology of tuberculosis. Lancet 367 938-940.
4. World Health Organization (2006) Global Tuberculosis Control: WHO Report 2006. (WHO/HTM/TB/2006) Geneva, Switzerland: World Health Organization
5. DE Snider Jr, MC Raviglione and A Kochi (1995) Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 273 220-226.
6. A Kochi (1991) The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72 1-6.
7. GW Comstock (1994) The International Tuberculosis Campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis 19 528-540.
8. PEM Fine (1995) Bacille Calmette-Guérin vaccines: a rough guide. Clin Infect Dis 20 11-14.
9. DW Smith (1985) Protective effect of BCG in experimental tuberculosis. Adv Tuberc Res 22 1-97.
10. NW Schluger (2001) Changing approaches to the diagnosis of tuberculosis. Am J Respir Crit Care Med 164 2020-2024.
11. JP Stevens and TM Daniel (1996) Bacille Calmette-Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 77 315-321.
12. TF Brewer and GA Colditz (1995) Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in healthcare workers. Clin Infect Dis 20 136-142.
13. PA Selwyn, D Hartel, VA Lewis, et al. (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320 545-550.
14. RW Ryder, MJ Oxtoby, M Mvula, et al. (1993) Safety and immunogenicity of bacille Calmette-Guérin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 122 697-702.
15. MM Braun and G Cauthen (1992) Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and bacillus Calmette-Guérin immunization. Pediatr Infect Dis J 11 220-227.
16. AB Bloch, GM Cauthen, IM Onorato, et al. (1994) Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271 665-671.
17. C Dye, MA Espinal, CJ Watt, et al. (2002) Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185 1197-1202.
18. Centers for Disease Control and Prevention (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—Worldwide, 2000–2004. MMWR 55(11), 301-305.
19. SW Dooley, ME Villarino, M Lawrence, et al. (1992) Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients. JAMA 267 2632-2635.
20. ML Pearson, JA Jereb, TR Frieden, et al. (1992) Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and healthcare workers. Ann Intern Med 117 191-196.
21. Centers for Disease Control and Prevention (1996) The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 45(RR-4), 1-18.
22. BR Bloom and CJL Murray (1992) Tuberculosis: commentary on a reemergent killer. Science 257 1055-1064.
23. D Morse, DR Brothwell and PJ Ucko (1964) Tuberculosis in ancient Egypt. Am Rev Respir Dis 90 524-541.
24. JR Starke and MHD Smith (1998) Tuberculosis. RD Feigin, JD Cherry (Eds) Textbook of Pediatric Infectious Diseases 4th ed. Philadelphia: WB Saunders 1196-1239.
25. JR Starke and AG Correa (1995) Management of mycobacterial infection and disease in children. Pediatr Infect Dis J 14 455-470.
26. MHD Smith (1989) Tuberculosis in children and adolescents. Clin Chest Med 10 381-395.
27. RL Nemir (1986) Perspectives in adolescent tuberculosis: three decades of experience. Pediatrics 78 399-404.
28. JG Vallejo, LT Ong and JR Starke (1994) Clinical features, diagnosis and treatment of tuberculosis in infants. Pediatrics 94 1-7.
29. S Perry and JR Starke (1993) Adherence to prescribed treatment and public health aspects of tuberculosis in children. Semin Pediatr Infect Dis 4 291-298.
30. MD Rossman and RL Mayock (1988) Pulmonary tuberculosis. D Schlossberg (Eds) Clinical Topics in Infectious Disease: Tuberculosis New York: Springer-Verlag 61-70.
31. MA Khan, DM Kovnat, B Bachus, et al. (1977) Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 62 31-38.
32. S Alvarez, C Shell and SL Berk (1987) Pulmonary tuberculosis in elderly men. Am J Med 82 602-606.
33. FM Gordin, G Slutkin, G Schecter, et al. (1989) Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings. Am Rev Respir Dis 139 1090-1093.
34. PES Palmer (1979) Pulmonary tuberculosis: usual and unusual radiographic presentations. Semin Roentgenol 14 204-242.
35. SC Chang, PY Lee and RP Perng (1987) Lower lung field tuberculosis. Chest 91 230-232.
36. PF Barnes, AB Bloch, PT Davidson, et al. (1991) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 324 1644-1650.
37. BE Jones, SMM Young, D Antoniskis, et al. (1993) Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148 1292-1297.
38. N Markowitz, N Hansen, PC Hopewell, et al. (1997) Incidence of tuberculosis in the United States among HIV-infected patients. Ann Intern Med 126 123-132.
39. PC Hopewell (1997) Tuberculosis in persons with human immunodeficiency virus infection: clinical and public health aspects. Semin Respir Crit Care Med 18 471-484.
40. AE Pitchenik and HA Rubinson (1985) The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 131 393-396.
41. R Long, B Maycher, M Scalcini and J Manfreda (1991) The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest 99 123-127.
42. LS Wasser, GW Shaw and W Talvera (1988) Endobronchial tuberculosis in the acquired immunodeficiency syndrome. Chest 94 1240-1244.
43. RW Shafter, DS Kim, JP Weiss, et al. (1991) Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 70 384-397.
44. DE Snider Jr, HL Rieder and GM Cauthen (1990) Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 141 347-351.
45. KE Schuitt and DA Powell (1978) Mycobacterial lymphadenitis in childhood. Am J Dis Child 132 675-677.
46. G Hussey, T Chisolm and M Kibel (1991) Miliary tuberculosis in children: a review of 94 cases. Pediatr Infect Dis J 10 832-836.
47. CA Doerr, Starke Jr and LT Ong (1995) Clinical and public health aspects of tuberculous meningitis in children. J Pediatr 127 27-33.
48. A Molavi and JL Le Frock (1985) Tuberculous meningitis. Med Clin North Am 69 315-331.
49. MM Floyd, VA Silcox, WD Jones Jr, et al. (1992) Separation of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids. J Clin Microbiol 30 1327-1330.
50. J Sauret, R Jolis, V Ausina, et al. (1992) Human tuberculosis due to Mycobacterium bovis: report of 10 cases. Tuber Lung Dis 73 388-391.
51. WH Feldman, R Davis, HE Moses, et al. (1943) An unusual mycobacterium isolated from sputum of a man suffering from pulmonary disease of long duration. Am Rev Tuberc 48 82-93.
52. D Wagner and LS Young (2004) Nontuberculous mycobacterial infections: A clinical review. Infection 32 257-270.
53. BA Brown-Elliott, DE Griffith and RJ Wallace Jr (2002) Newly described or emerging human species of nontuberculous mycobacteria. Infect Dis Clin North Am 16 187-220.
54. K Asiedu, R Scherpbier and M Raviglione (2000) Buruli ulcer— Mycobacterium ulcerans infection Geneve, Switzerland: World Health Organization Global Buruli Ulcer Initiative
55. DM Musher (2003) How contagious are common respiratory tract infections. N Eng J Med 348(13), 1256-1266.
56. RL Riley (1957) The J. Burns Amberson lecture: Aerial dissemination of pulmonary tuberculosis. Am Rev Tuberc Pulm Dis 76 931-941.
57. IM Orme (1998) The immunopathogenesis of tuberculosis: a new working hypothesis. Trends Microbiol 6 94-97.
58. TM Lasco, OC Turner, L Cassone, et al. (2004) Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect Immun 72 1147-1149.
59. OC Turner, RJ Basaraba and IM Orme (1967) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 71:864–871, 2003. 60. Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residual of the primary infection or exogenous reinfection. Am Rev Respir Dis 95 729-745.
60. JW Raleigh and R Weichelhausen (1973) Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing. Am Rev Respir Dis 108 639-642.
61. E Nardell, B McInnis, B Thomas, et al. (1986) Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 315 1570-1575.
62. CY Chiang and LW Riley (2005) Exogenous reinfection in tuberculosis. Lancet Infect Dis 5 629-636.
63. P Laochumroonvorapong, J Wang, CC Liu, et al. (1997) Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect Immun 65 127-132.
64. SM Irwin, AA Izzo, SW Dow, et al. (2005) Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 73 5809-5816.
65. AM Cooper, C D'Souza, AA Frank and IM Orme (1997) The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perfoin- or granzyme-mediated cytolytic mechanisms. Infct Immun 65 1317-1320.
66. JM Grange (1997) Vaccination against tuberculosis: past problems and future hopes. Semin Respir Crit Care Med 18 459-470.
67. IM Orme, JL Flynn and BR Bloom (1995) The role of CD8 + T cells in immunity to tuberculosis. Trends Microbiol 1 77-78.
68. A Molloy, P Laochumroonvorapong and G Kaplan (1995) Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. J Exp Med 180 1499-1509.
69. JS Park, MH Tamayo, M Gonzalez-Juarrero, et al. (2006) Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol 79 80-86.
70. IM Orme, P Anderson and WH Boom (1993) T cell response to Mycobacterium tuberculosis. J Infect Dis 167 1481-1497.
71. TR Mosmann (1991) Regulation of immune response by T cells with different cytokine secretor phenotypes: role of a new cytokine, cytokine synthesis inhibitory factor (IL-10). Int Arch Allergy Appl Immunol 94 110-115.
72. PA Bretscher (1992) A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol Today 13 342-345.
73. SA Khader, JE Perl, K Sakamoto, et al. (2005) IL-23 compensates for the absence of IL-12p70 is available. J Immunol 175 788-795.
74. HM Surcel, M Troyer-Blomberg, S Paulie, et al. (1994) Th1/Th2 profiles in tuberculosis based on proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81 171-176.
75. V Schauf, WN Rom, KA Smith, et al. (1993) Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis 168 1056-1059.
76. GAW Rook and R Hernandez-Pando (1996) The pathogenesis of tuberculosis. Am Rev Microbiol 50 259-284.
77. R Hernandez-Pando and GAW Rook (1994) The role of TNF in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82 591-595.
78. L Brandt, JF Cunha, AW Olsen, et al. (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block mulitplication of BCG and induction of protective immunity with tuberculosis. Infec Immun 70 672-678.
79. VH Springett and I Sutherland (1994) A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis 75 227-233.
80. PE Fine (2001) BCG: the challenge continues. Scand J Infect Dis 33 243-245.
81. KHK Hsu (1983) Tuberculin reaction in children treated with isoniazid. Am J Dis Child 137 1090-1092.
82. JB Hardy (1946) Persistence of hypersensitivity to old tuberculin following primary tuberculosis in childhood: a long-term study. Am J Public Health 36 1417-1426.
83. TP Howard and DA Soloman (1988) Reading the tuberculin skin test: who, when and how? Arch Intern Med 148 2457-2459.
84. P Steiner, M Rao, MS Victoria, et al. (1980) Persistently negative tuberculin reactions: their presence among children culture-positive for Mycobacterium tuberculosis. Am J Dis Child 134 747-750.
85. DC Kent and R Schwartz (1967) Active pulmonary tuberculosis with negative tuberculin skin reactions. Am Rev Respir Dis 95 411-418.
86. American Thoracic Society (1990) Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 142 725-735.
87. RE Huebner, MF Schein and JB Bass Jr (1993) The tuberculin skin test. Clin Infect Dis 17 968-975.
88. RJ O'Brien, LJ Geiter, DE Snider Jr, et al. (1987) The epidemiology of nontuberculous mycobacterial diseases in the United States. Am Rev Respir Dis 135 1007-1014.
89. LB Edwards, FA Acquaviva, VT Livesay, et al. (1969) An atlas of sensitivity to tuberculin, PPD-B and histoplasmin in the United States. Am Rev Respir Dis 99 1-99.
90. American Thoracic Society and the Centers for Disease Control and Prevention (2000) Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 161 1376-1395.
91. RL Nemir and A Teichner (1983) Management of tuberculin reactions in children and adolescents previously vaccinated with BCG. Pediatr Infect Dis J 2 446-451.
92. R Menzies and B Vissandjee (1992) Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 145 621-625.
93. M Lifschitz (1965) The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics 36 624-627.
94. O Horwitz and K Bunch-Christensen (1972) Correlation between tuberculin sensitivity after 2 months and 5 years among BCG-vaccinated subjects. Bull World Health Organ 47 49-58.
95. GW Comstock, LB Edwards and H Nabangxang (1971) Tuberculin sensitivity eight to fifteen years after BCG vaccination. Am Rev Respir Dis 103 572-575.
96. JH Margus and Y Khassis (1965) The tuberculin sensitivity in BCG vaccinated infants and children in Israel. Acta Tuberc Pneumonol Scand 46 113-122.
97. S Landi, MJ Ashley and S Grzybowski (1967) Tuberculin sensitivity following the intradermal and multiple puncture methods of BCG vaccination. Can Med Assoc J 97 222-225.
98. MJ Ashley and CO Siebenmann (1967) Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts. Can Med Assoc J 97 1335-1338.
99. EB Kemp, RB Belshe and DF Hoft (1996) Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis 174 113-119.
100. JH Joncas, R Robitaille and T Gauthier (1975) Interpretation of the PPD skin test in BCG-vaccinated children. Can Med Assoc J 113 127-128.
101. K Magnus and LB Edwards (1955) The effect of repeated tuberculin testing on post-vaccination allergy. Lancet 1 643-644.
102. I Ildirim, M Hacimustafaoglu and B Ediz (1995) Correlation of tuberculin induration with the number of bacillus Calmette-Guérin vaccines. Pediatr Infect Dis J 14 1060-1063.
103. TK Young and S Mirdad (1992) Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuber Lung Dis 73 94-100.
104. RL Sepulveda, IM Heiba, C Naverrete, et al. (1994) Tuberculin reactivity after newborn BCG immunization in mono- and dizygotic twins. Tuber Lung Dis 75 138-143.
105. RL Sepulveda, IM Heiba, A King, et al. (1994) Evaluation of tuberculin reactivity in BCG-immunized siblings. Am J Respir Crit Care Med 149 620-624.
106. ML Garly, C Bale, CL Martins, et al. (2002) BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens. Vaccine 20 468-474.
107. S Karalliede, LP Katugha and CG Uragoda (1987) The tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 68 33-38.
108. NJ Thompson, JL Glassroth, DE Snider, et al. (1979) The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 119 587-597.
109. JB Bass Jr and RA Serio (1982) The use of repeat skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 123 394-396.
110. RL Sepulveda, C Burr, X Ferrer, et al. (1988) Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with bacillus Calmette-Guérin at birth in Santiago, Chile. Pediatr Infect Dis J 7 578-581.
111. RL Sepulveda, X Ferrer, C Latrach, et al. (1990) The influence of Calmette-Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis 142 24-28.
112. HW Horowitz, BB Luciano, JR Kadel, et al. (1995) Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guérin: recent Mycobacterium tuberculosis infection or booster effect? Am J Infect Control 23 181-187.
113. JR Starke and K Taylor-Watts (1989) Tuberculosis in the pediatric population of Houston, Texas. Pediatrics 84 28-35.
114. DL Abadco and P Steiner (1992) Gastric lavage is better than bronchoalveolar lavage for isolation of Mycobacterium tuberculosis in childhood pulmonary tuberculosis. Pediatr Infect Dis J 11 735-738.
115. IJ Strumpf, AY Tsang and JW Sayne (1979) Reevaluation of sputum staining for the diagnosis of pulmonary tuberculosis. Am Rev Respir Dis 119 599-602.
116. BA Lipsky, J Gates, FC Tenover, et al. (1984) Factors affecting the clinical value of microscopy for acid-fast bacilli. Rev Infect Dis 6 214-222.
117. F Gordin and G Slutkin (1990) The validity of acid-fast smears in the diagnosis of pulmonary tuberculosis. Arch Pathol Lab Med 114 1025-1027.
118. KD Eisenach, MD Sifford, MD Cane, et al. (1991) Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction. Am Rev Respir Dis 144 1160-1163.
119. A Noordhock, A Kolk, G Bjune, et al. (1994) Sensitivity and specificity of polymerase chain reaction for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 32 277-284.
120. C Pierre, C Oliver, D Lecoissier, et al. (1993) Diagnosis of primary tuberculosis in children by amplification and detection of mycobacterial DNA. Am Rev Respir Dis 147 420-424.
121. KC Smith, JR Starke, K Eisenach, et al. (1996) Detection of Mycobacterium tuberculosis in clinical specimens from children using a polymerase chain reaction. Pediatrics 97 155-160.
122. D Gomez-Pastrana, R Torronteras, P Caro, et al. (2001) Comparison of Amplicor, in-house polymerase chain reaction, and conventional culture for the diagnosis of tuberculosis in children. Clin Infect Dis 32 17-22.
123. E Julian, M Cama, P Martinez and M Luquin (2001) An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis: Tween 20 interference in the assay. J Immunol Methods 252 21-30.
124. KK Singh, X Zhang, AS Patibandla, et al. (2001) Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences. Infect Immun 69 4185-4191.
125. TA Tessema, B Hamasur, G Bjune, et al. (2001) Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis center. Scand J Infect Dis 33 279-284.
126. B Hamasur, J Bruchfeld, M Haile, et al. (2001) Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Microbiol Meth 45 41-52.
127. S Pottumarthy, VC Wells and AJ Morris (2000) A comparison of seven tests for serological diagnosis of tuberculosis. J Clin Microbiol 38 2227-2231.
128. G Ferrara, M Losi, R D'Amico, et al. (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519), 1328-1334.
129. K Al Zahrani, J.H. Al Jahdali H, L Poirier, et al. (2000) Accuracy and utility of commercially available amplification and serologic tests for the diagnosis of minimal pulmonary tuberculosis. Am J Respir Crit Care Med 162 1323-1329.
130. M Pai, S Kalantri and K Dheda (2006) New tools and emerging technologies for the diagnosis of tuberculosis: Part 1. Lanent tuberculosis. Exper Rev Mol Diagn 6(3), 413-422.
131. GH Mazurek, J Jereb, P LoBue, et al. (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 49-55.
132. GH Mazurek, PA LoBue, CL Daley, et al. (2001) Comparison of a whole-blood interferon [gamma] assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286 1740-1747.
133. AB Migliori, A Borghesi, P Rossnigo, et al. (1992) Proposal for an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. Tuber Lung Dis 73 145-149.
134. BJ Marais, RP Gie, HS Schaaf, et al. (2006) Childhood pulmonary tuberculosis Old wisdom and new challenges. Am J Respir Crit Care Med 173 1078-1090.
135. American Thoracic Society (1994) Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149 1359-1374.
136. American Thoracic Society and the Centers for Disease Control and Prevention (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161(Suppl), S221-S247.
137. American Academy of Pediatrics (2006) Tuberculosis. LK Pekering (Eds) 2006 Red Book: Report of the Committee on Infectious Diseases, 27th ed Elk Grove Village, IL: American Academy of Pediatrics 678-698.
138. Centers for Disease Control and Prevention (2000) Core Curriculum on Tuberculosis: What a Clinician Should Know 4th ed. Atlanta: Centers for Disease Control and Prevention
139. Joint Tuberculosis Committee of the British Thoracic Society (1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 53 536-548.
140. World Health Organization (1997) Treatment of Tuberculosis: Guidelines for National Programmes 2nd ed Geneva: World Health Organization; Global Tuberculosis Programme
141. World Health Organization (2001) Global Tuberculosis Control: WHO Report 2001 (WHO/CDS/TB/2001.287) Geneva: World Health Organization
142. EI Corbett, CJ Watt, N Walker, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 1009-1021.
143. WHO (2006) Global tuberculosis control: surveillance, planning, financing Geneva: World Health Organization 242.
144. C Dye, CJ Watt, DM Bleed, et al. (2005) Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 2767-2775.
145. MA Estpinal, A Laszlo, L Simonsen, et al. (2001) Global trends in resistance to antituberculosis drugs. N Engl J Med 344 1294-1303.
146. IUATALD WHO (2004) Anti-tuberculosis drug resistance in the world: third global report Geneva: World Health Organization 299.
147. C Dye (2002) Espinal MA, Watt CJ, et al. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185 1197-1202.
148. A Kochi (2001) The global tuberculosis situation and the new control strategy of the World Health Organization 1991. Bull World Health Organ 79 71-75.
149. DE Snider Jr, MF Cantwell, GM Cauthen, et al. (1994) Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 272 535-539.
150. CDC, Reported tuberculosis in the United States, 2004. Atlanta, GA: U.S. Department of Health and Human Services, DCD, September 2005. Online. Available at: www.cdc.gov/nchstp/tb/surv/surv2004/PDF/Table1.pdf Accessed September 24, 2006
151. Centers for Disease Control and Prevention (2007) Trends in tuberculosis incidence—United States, 2006. MMWR 56 245-272.
152. AMC Rose, JM Watson, C Graham, et al. (2001) Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 56 173-179.
153. MT McKenna, E McCray and IM Onorato (1995) The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 332 1071-1076.
154. XT Ussery, SE Valway, M McKenna, et al. (1996) Epidemiology of tuberculosis among children in the United States: 1985 to 1994. Pediatr Infect Dis J 15 697-704.
155. R Parslow, NA El-Shimy, BC Cundall and PA McKinney (2001) Tuberculosis, deprivation, and ethnicity in Leeds, UK, 1982–1997. Arch Dis Child 84 109-113.
156. Centers for Disease Control and Prevention (1991) Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988–1991. MMWR 40 585-591.
157. World Bank (1993) World Development Report: 1993 Washington, DC: The World Bank
158. Centers for Disease Control and Prevention (2007) Extensively drug-resistant tuberculosis—United States, 1993–2006. MMWR 56 250-253.
159. CS Wells, EW Flahiff and HH Smith (1944) Results obtained in man with the use of a vaccine of heat-killed tubercle bacilli. Am J Hyg 40 116-126.
160. Great Britain Medical Research Council (1959) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early life. Br Med J 2 379-396.
161. B Weill-Halle (1957) Oral vaccination. SR Rosenthal (Eds) BCG Vaccination Against Tuberculosis Boston: Little, Brown 175-182.
162. F Luelmo (1982) BCG vaccination. Am Rev Respir Dis 125(Suppl), 70-72.
163. International Union Against Tuberculosis (1978) Phenotypes of BCG vaccines seed lot strains: results of an international cooperative study. Tubercle 59 139-142.
164. KN Lewis, R Liao, KM Guinn, et al. (2003) Deletion of RD1 from Myobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis 187(1), 117-123.
165. JB Milstien and JJ Gibson (1990) Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 68 93-108.
166. TW Osborn (1983) Changes in BCG strains. Tubercle 64 1-13.
167. KA Jensen (1946) Practice of the Calmette vaccination. Acta Tuberc Scand 20 1-45.
168. RF Jacox and GM Meade (1949) Variation in the duration of tuberculin skin sensitivity produced by two strains of BCG. Am Rev Tuberc 60 541-546.
169. RJ Dubos, CH Pierce and WB Schaefer (1953) Antituberculous immunity induced in mice by vaccination with living cultures of attenuated tubercle bacilli. J Exp Med 9 207-220.
170. RJ Dubos and CH Pierce (1956) Differential characteristics in vitro and in vivo of several substrains of BCG. I. Multiplication and survival in vitro. Am Rev Tuberc Pulm Dis 74 655-666.
171. CH Pierce and RJ Dubos (1956) Differential characteristics in vitro and in vivo of several substrains of BCG. II. Morphologic characteristics in vitro and in vivo. Am Rev Tuberc Pulm Dis 74 667-682.
172. CH Pierce, RJ Dubos and WB Schaefer (1956) Differential characteristics in vitro and in vivo of several substrains of BCG. III. Multiplication and survival in vivo. Am Rev Tuberc Pulm Dis 74 683-698.
173. RJ Dubos and CH Pierce (1956) Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness. Am Rev Tuberc Pulm Dis 74 699-717.
174. RJ Wallace Jr, Y Zhang and GH Mazurek (1995) Genetic differences between BCG substrains. Tuber Lung Dis 76 43-50.
175. M Gheorghiu (1990) The present and future role of BCG vaccine in tuberculosis control. Biologicals 18 135-141.
176. VM Sekuis, H Freudenstein and JL Sirks (1977) Report on results of a collaborative assay of BCG vaccines organized by the International Association of Biological Standardization. J Biol Stand 5 85-109.
177. M Gheorghiu and PH Lagrange (1983) Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. Ann Immunol 134C 124-147.
178. NG Formukong, JN Dale, TW Osborn, et al. (1992) Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. J Appl Bacteriol 72 126-133.
179. MA Behr (2002) BCG-different strains, different vaccines? Lancet Infect Dis 2 86-92.
180. D Smith, C Harding, J Chan, et al. (1979) Potency of 10 BCG vaccines organized by the IABS. J Biol Stand 7 179-197.
181. MA Behr (2001) Correlation between BCG genomics and protective efficacy. Scand J Infect Dis 33 249-252.
182. GW Comstock (1988) Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 138 479-480.
183. Tuberculosis Control Program and Expanded Programme on Immunization (1986) Efficacy of infant BCG immunization. Wkly Epidemiol Rec 28 216-218.
184. TM Pollock (1959) BCG vaccination in man. Tubercle 40 339-412.
185. HG Lehman, H Englehardt, H Freudenstein, et al. (1979) BCG vaccination of neonates, infants, school children and adolescents. II. Safety of vaccine with strain 1331 Copenhagen. Dev Biol Stand 43 133-136.
186. Expanded Programme on Immunization/Biologicals Unit (1988) Lymphadenitis associated with BCG immunization. Wkly Epidemiol Rec 63 381-388.
187. Expanded Programme on Immunization/Biologicals Unit (1989) BCG-associated lymphadenitis in infants. Wkly Epidemiol Rec 30 231-232.
188. L Kroger, E Brander, M Korppi, et al. (1994) Osteitis after newborn vaccination with three different bacillus Calmette-Guérin vaccines: twenty-nine years of experience. Pediatr Infect Dis J 12 113-116.
189. MA Behr and PM Small (1997) Declining efficacy of BCG strains over time? A new hypothesis for an old controversy [abstract]. Am J Respir Crit Care Med 155 A222.
190. M Harboe and S Nagel (1984) MPB70, a unique antigen of Mycobacterium bovis BCG. Am Rev Respir Dis 129 444-452.
191. C Abou-Zeid, GAW Rook, DE Mannikin, et al. (1987) Effect of the method of preparation of bacille Calmette-Guérin vaccine on the properties of four daughter strains. J Appl Bacteriol 63 449-453.
192. BCG TICE® BCG Live. Online. Available at: www.pdr.net Accessed June 3, 2002
193. PO Devadoss, ME Klegerman and MJ Groves (1991) A scanning electron microscope study of mycobacterial developmental stages in commercial BCG vaccines. Curr Microbiol 22 247-252.
194. M Gheorghiu (1988) The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand 15 15-26.
195. PEM Fine, IAM Carneiro, JB Milstien and CJ Clements (1999) Issues Relating to the Use of BCG in Immunization Programmes: A Discussion Document Geneva: World Health Organization, Department of Vaccines and Biologicals
196. World Health Organization, Immunization Standars, UN Prequalified Vaccines-BCG as of August 2006. Online. Available at: www.who.int/immunization-standards/vaccine_quality/bcg/en/index.html/ Accessed Agust 6, 2006
197. M Gheorghiu, J Augier and PH Lagrange (2006) Maintenance and control of the French BCG strain 1173P2 (primary and secondary seed lots). Bull Inst Pasteur 81:281–288, 1983.195. Gorak-Stolinska P, Weir RE, Floyd S, et al. Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 24(29–30), 5726-5733.
198. HG ten Dam (1984) Research on BCG vaccination. Adv Tuberc Res 21 79-106.
199. HG ten Dam, C Fillastre, C Conge, et al. (1970) The use of jet injectors in BCG vaccination. Bull World Health Organ 43 707-720.
200. AM Darmanger, SM Nekzad, M Kuis, et al. (1977) BCG vaccination by bifurcated needle in a pilot BCG vaccination programme. Bull World Health Organ 55 49-61.
201. K Birkhaug (1941) An experimental and clinical investigation of a percutaneous (Rosenthal) method of BCG vaccination. Nord Med 10 1224-1231.
202. IL Briggs and C Smith (1957) BCG vaccination by the multiple puncture method in northern Rhodesia. Tubercle 38 107-111.
203. AH Griffith (1959) BCG vaccination by multiple puncture. Lancet 1 1170-1172.
204. DW Stainer and S Landi (1986) Stability of BCG vaccines. Dev Biol Stand 58 119-125.
205. PG Smith (1987) Case-control studies of the efficacy of BCG against tuberculosis. In International Union Against Tuberculosis. Proceedings of the XXVIth IUAT World Conference on Tuberculosis and Respiratory Diseases Singapore: Japan, Professional Postgraduate Services International 73-79.
206. VW Filho, EA de Castilho, LC Rodrigues, et al. (1990) Effectiveness of BCG vaccination against tuberculous meningitis: a case-control study in Sao Paulo, Brazil. Bull World Health Organ 68 69-74.
207. BB Trunz, PEM Fine and C Dye (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367 1173-1180.
208. I Sutherland and I Lindgren (1979) The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 60 225-231.
209. DW Smith, G Harding, J Chan, et al. (1979) Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea pigs. J Biol Stand 7 179-197.
210. KA Jensen, G Bindsleu and J Holm (1935) Experimental studies on the development of tuberculous infection in allergic and non-allergic animals. I. Development of tuberculous infection in the lungs after inhalation of virulent tubercle bacilli. Acta Tuberc Scand 9 27-46.
211. FM Levy, GA Conge, JF Pasquier, et al. (1961) The effect of BCG-vaccination on the fate of virulent tubercle bacilli in mice. Am Rev Respir Dis 84 28-36.
212. DW Smith, DN McMurray, EH Wiegeshaus, et al. (1970) Host-parasite relationship in experimental airborne tuberculosis. IV. Early events in the course of infection in vaccinated and nonvaccinated guinea pigs. Am Rev Respir Dis 102 937-949.
213. D Ordway, M Henao-Tamayo, IM Orme and M Gonzalez-Juarrero (2005) Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J Immunol 175 3873-3881.
214. JAK Browne, MM Stone and I Sutherland (1966) BCG vaccination of children against leprosy in Uganda: first results. Br Med J 1 7-14.
215. JM Ponninghaus, PEM Fine, JAC Sterne, et al. (1992) Efficacy of BCG vaccine against leprosy and tuberculosis in Northern Malawi. Lancet 339 636-639.
216. Karonga Prevention Trial Group (1996) Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis. Lancet 348 17-24.
217. L Trnka, D Dankova and E Svandova (1994) Six years’ experience with the discontinuation of BCG vaccine. 4. Protective effect of BCG against Mycobacterium avium-intracellulare complex. Tuber Lung Dis 75 348-352.
218. V Romanus, A Svensson and HO Hollander (1992) The impact of changing BCG coverage on tuberculosis in Swedish children between 1969 and 1989. Tuber Lung Dis 73 150-161.
219. MO Ota, J Vekemans, SE Schlegel-Haueter, et al. (2002) Influence of Myobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 168(2), 919-925.
220. BA Covert, JS Spencer, IM ORme and JT Belisle (2001) The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis. Proteomics 1 574-586.
221. IM Orme, P Andersen and WH Boom (1993) T cell response to Mycobacterium tuberculosis. J Infect Dis 167 1481-1497.
222. PEM Fine (1989) The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11(Suppl 2), S353-S359.
223. PEM Fine, JM Ponnighaus and NP Maine (1986) The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Lepr Rev 57(Suppl 12), S274-S283.
224. PEM Fine, JAC Sterne, JM Ponnighaus, et al. (1994) Delayed type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 344 1245-1249.
225. Tuberculosis Prevention Trial (1979) Trial of BCG vaccines in South India for tuberculosis prevention: first report. Bull World Health Organ 57 819-827.
226. SP Tripathy (1987) Fifteen-year follow-up of the Indian BCG prevention trial. Bull Int Union Tuberc Lung Dis 62 69-73.
227. FA al-Kassimi, MS al-Hajjaj, IO al-Orainey, et al. (1995) Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 152 1575-1578.
228. JM Grange (1986) Environmental mycobacteria and BCG vaccination. Tubercle 67 1-4.
229. AD Pithie, M Rahelu, DS Kumararatne, et al. (1992) Generation of cytolytic T cells in individuals infected with Mycobacterium tuberculosis and vaccinated with BCG. Thorax 47 695-701.
230. PEM Fine (1984) Leprosy and tuberculosis: an epidemiological comparison. Tubercle 65 137-153.
231. MO Ota, T Goetghebuer, J Vekemans, et al. (2006) Dissociation between tuberculin skin test and in vitro IFN-g?responses following neonatal BCG vaccination. J Trop Pediatr 52(2), 136-140.
232. NW Schluger and WN Rom (1998) The host immune response to tuberculosis. Am J ResTpir Crit Care Med 157 679-691.
233. T Klunner, T Bartels, M Vordermeier, et al. (2001) Immune reactions of CD4- and CD8-positive T cell subpopulations in spleen and lymph nodes of guinea pigs after vaccination with bacillus Calmette-Guérin. Vaccine 19(15–16), 1968-1977.
234. NV Serbina, C-C Liu, CA Scanga and JL Flynn (2000) CD8 + CTL from lungs of Mycobacteria tuberculosis-infected mice express perforin in vivo and lyse infected macrophages. J Immunol 165 353-363.
235. S Stenger and RL Modlin (1998) Cytotoxic T cell responses to intracellular pathogens. Curr Opin Immunol 10 471-477.
236. P Andersen, ME Munk, JM Pollock and TM Doherty (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356 1099-1104.
237. GH Mazurek, PA LoBue, CL Daley, et al. (2001) Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286 1740-1747.
238. PC Hill, RH Brookes, IM Adetifa, et al. (2006) Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 117(5), 1542-1548.
239. JD Clemens, JJH Chuong and AR Feinstein (1983) The BCG controversy: a methodological and statistical reappraisal. JAMA 249 2362-2369.
240. PEM Fine and LC Rodrigues (1990) Modern vaccines: mycobacterial diseases. Lancet 335 1016-1020.
241. ME Wilson, HV Fineberg and GA Colditz (1995) Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect Dis 20 982-991.
242. TF Brewer and GA Colditz (1995) Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 20 126-135.
243. PEM Fine (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 1339-1345.
244. I Miceli, IN de Kantor, D Colaiacovo, et al. (1988) Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 17 629-634.
245. PAM Camargos, MDC Guimaraes and CMF Antunes (1988) Risk assessment for acquiring meningitis tuberculosis among children not vaccinated with BCG: a case control study. Int J Epidemiol 17 193-197.
246. E Bonifachich, M Chort, A Astigarraga, et al. (2006) Protective effect of bacillus Calmette-Guérin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease A case-control study in Rosario, Argentina. Vaccine 24 2894-2899.
247. A Bagshawe, GC Scott, DA Russell, et al. (1989) BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bull World Health Organ 67 389-399.
248. SJ Stanley, C Howland, MM Stone and I Sutherland (1981) BCG vaccination of children against leprosy in Uganda: final results. J Hyg (Camb) 87 235-248.
249. J Bertolli, C Pangi, R Frerichs and ME Halloran (1997) A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol 26 888-895.
250. K Lwin, T Sundaresan, MM Gyi, et al. (1985) BCG vaccination of children against leprosy: fourteen year findings of the trial in Burma. Bull World Health Organ 63 1069-1078.
251. NV Thuc, L Abel, VC Lap, et al. (1994) Protective effect of BCG against leprosy and its subtypes: a case control study in Southern Viet Nam. Int J Lepr 62 532-538.
252. JM Ponnighaus, PEM Fine, JAC Sterne, et al. (1992) Efficacy of BCG against leprosy and tuberculosis in Northern Malawi. Lancet 339 636-639.
253. SP Tripathy (1983) The case for BCG. Ann Natl Acad Med Sci 19 11-21.
254. PA Orege, PEM Fine, SB Lucas, et al. (1993) Case control study of BCG vaccination as a risk factor for leprosy and tuberculosis in Western Kenya. Int J Lepr 61 542-549.
255. GW Comstock (1994) Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials 15 247-276.
256. JR Starke and KK Connelly (1994) Bacille Calmette-Guérin (BCG) vaccine. Vaccines 2nd ed. Philadelphia: WB Saunders 439-473.
257. KC Smith and JR Starke (1999) Bacille Calmette-Guérin (BCG) vaccine. Vaccines, 3rd ed Philadelphia: WB Saunders 111-139.
258. KC Smith and JR Starke (2004) Bacille Calmette-Guérin (BCG) vaccine. Vaccines 4th ed. Philadelphia: WB Saunders 179-209.
259. SC Stein and JD Aronson (1953) The occurrence of pulmonary lesions in BCG-vaccinated and unvaccinated persons. Am Rev Tuberc 68 695-712.
260. SR Rosenthal, E Loewinsohn, ML Graham, et al. (1961) BCG vaccination against tuberculosis in Chicago: a twenty-year study statistically analyzed. Pediatrics 28 622-641.
261. PD Hart and I Sutherland (1977) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final report to the Medical Research Council. Br Med J 2 293-295.
262. NE Aronson, M Santosham, GW Comstock, et al. (2004) Long-term efficacy of BCG vaccine in American Indians and Alaska Natives. JAMA 291 2086-2091.
263. CE Palmer, LW Shaw and GW Comstock (1958) Community trials of BCG vaccination. Am Rev Tuberc Pulm Dis 77 877-907.
264. J Frimodt-Moller, J Thomas and R Parthasanathy (1964) Observations on the protective effect of BCG vaccination in a south Indian rural population. Bull World Health Organ 30 545-574.
265. J Frimodt-Moller, G Acharyulu and K Pillai (1973) Observations on the protective effect of BCG vaccination in a south Indian rural population: fourth report. Bull Int Union Tuberc 48 40-52.
266. G Comstock and L Shaw (1960) Controlled trial of BCG vaccination in a school population. Public Health Rep 75 583-594.
267. G Comstock and R Webster (1969) Tuberculosis studies in Muscogee County, Georgia: VII. A 20 year evaluation of BCG vaccination in a school population. Am Rev Respir Dis 100 839-845.
268. G Comstock and C Palmer (1966) Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis 93 171-183.
269. GW Comstock (1988) Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 138 479-480.
270. JL Stanford, MJ Shield and GAW Rook (1981) How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 62 55-62.
271. GAW Rook, GM Bahr and JL Stanford (1981) The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 62 63-68.
272. PE Fine, S Floyd, JL Stanford, et al. (2001) Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect 126 379-387.
273. LB Edwards and CE Palmer (1968) Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci 154 140-148.
274. CE Palmer and L Hopwood (1962) Effect of previous infection with unclassified mycobacteria on survival of guinea pigs challenged with virulent tubercle bacilli. Bull Int Union Tuberc 32 389-391.
275. ML Edwards, JM Goodrich, D Muller, et al. (1982) Infection with Mycobacterium avium-intracellulare and the protective effects of bacilli Calmette-Guérin. J Infect Dis 145 733-741.
276. L Brandt, J Feino Cunha, A Weinreich Olsen, et al. (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tubercusis. Infect Immun 70(2), 672-678.
277. Tuberculosis Research Centre (ICMR), Chennai, India. Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-sanalysis of 15-year data from a double-blind randomized control trial in south India. Indian J Med Res 123 119-124.
278. PEM Fine (1981) Immunogenetics of susceptibility to leprosy, tuberculosis and leishmaniasis: an epidemiological perspective. Int J Lepr 49 437-454.
279. T Di Pletrantonio and E Schurr (2005) Mouse models for the genetic study of tuberculosis susceptibility. Brief Funct Genomic Proteomic 4(3), 277-292.
280. E Skamene (1989) Genetic control of susceptibility to mycobacterial infections. Rev Infect Dis 11(Suppl 2), S394-S399.
281. SM Vidal, D Malo, K Vogan, et al. (1993) Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73 469-485.
282. L Bulat-Kardum, GE Etokebe, J Knezevic, et al. (2006) Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A, T-56C) and susceptibility to tuberculosis. Scand J Immunol 63 142-150.
283. D Mansouri, P Adimi, M Mirsaeidi, et al. (2005) Inherited disorders of the IL-12-IFN-gamma axis in patients with disseminated BCG infection. Eur J Pediatr 164 753-757.
284. YH Hsu, CW Chen, HS Sun, et al. (2006) Association of NRAMP 1 gene polymorphism with susceptibility to tuberculosis in Taiwanese aboriginals. J Formos Med Assoc 105 363-369.
285. H Pan, BS Yan and M Rojas (2005) Ipr1 gene mediates innate immunity to tuberculosis. Nature 43–4 709-711.
286. H Li, TT Zhang, YQ Zhou, et al. (2006) SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis 10 2-12.
287. R Dubos (1964) Acquired immunity to tuberculosis. Am Rev Respir Dis 90 505-515.
288. MK Cohen, RA Bartow, CL Mintzer, et al. (1987) Effect of diet and genetics on Mycobacterium bovis BCG vaccine efficacy in inbred guinea pigs. Infect Immun 55 314-319.
289. DN McMurray, MS Kimball, CL Tetzlaff, et al. (1986) Effects of protein deprivation and BCG vaccination on alveolar macrophage function in pulmonary tuberculosis. Am Rev Respir Dis 133 1081-1085.
290. G Dai, S Phalen and DN McMurray (1998) Nutritional modulation of host responses to mycobacteria. Front Biosci 3 e110-e122.
291. S Padungchan, S Konjanart, S Kasiratta, et al. (1986) The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. Bull World Health Organ 64 247-258.
292. J Jason, LK Archibald, OC Nwanyanwu, et al. (2002) Vitamin A levels and immunity in humans. Clin Diagn Lab Immunol 9 616-621.
293. I Malhotra, P Mungai, A Wamachi, et al. (1999) Helminth- and bacillus Calmette-Guérin; induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 162(11), 6843-6848.
294. JA Hank, JK Chan, ML Edwards, et al. (1981) Influence of the virulence of Mycobacterium tuberculosis on protection induced by bacilli Calmette-Guérin in guinea pigs. J Infect Dis 143 734-738.
295. JE Ziegler, ML Edwards and DW Smith (1985) Exogenous reinfection in experimental airborne tuberculosis. Tubercle 66 121-128.
296. WW Stead (1965) The pathogenesis of pulmonary tuberculosis among older persons. Am Rev Respir Dis 91 811-822.
297. K Styblo (1980) Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 20 1-63.
298. KD Eisenach, JT Crawford and JH Bates (1986) Genetic relatedness among strains of the Mycobacterium tuberculosis complex. Am Rev Respir Dis 133 1065-1068.
299. CL Daley, PM Small, GF Schecter, et al. (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 326 231-235.
300. PG Smith (1982) Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method. Tubercle 62 23-35.
301. PEM Fine (1988) BCG vaccination against tuberculosis and leprosy. Br Med Bull 44 693-703.
302. K Murtagh (1980) Efficacy of BCG [letter]. Lancet 1 423.
303. B Chavalittamrong, S Chearskul and M Tuchinda (1986) Protective value of BCG vaccination in children in Bangkok, Thailand. Pediatr Pulmonol 2 202-205.
304. I Micheli, IN de Kantor, D Colaiacovo, et al. (1988) Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 17 629-634.
305. S Sirinavin, T Chotpitayasunondh, S Suwanjutha, et al. (1991) Protective efficacy of neonatal bacillus Calmette-Guérin vaccination against tuberculosis. Pediatr Infect Dis J 10 359-365.
306. Effectiveness of BCG vaccination in Great Britain in 1978: a report from the research committee of the British Thoracic Association. Br J Dis Chest 74 215-227.
307. RG Ferguson and AB Simes (1949) BCG vaccination of Indian infants in Saskatchewan. Tubercle 30 5-11.
308. HM Curtis, I Leck and FN Bamford (1984) Incidence of childhood tuberculosis after neonatal BCG vaccination. Lancet 1 145-148.
309. A Shannon, P Kelly, M Lucey, et al. (1991) Isoniazid resistant tuberculosis in a school outbreak: the protective effect of BCG. Eur Respir J 4 778-782.
310. LC Rodriques, ON Gill and PG Smith (1991) BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. J Epidemiol Community Health 45 78-80.
311. GE Packe and JA Innes (1988) Protective effect of BCG vaccination in infant Asians: a case-control study. Arch Dis Child 63 277-281.
312. S Houston, A Fanning, CL Soskolne, et al. (1990) The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis: a case-control study in treaty Indians, Alberta, Canada. Am J Epidemiol 131 340-347.
313. TK Young and ES Hershfield (1986) A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians. Am J Public Health 76 783-786.
314. P Blin, HG Delolme, JD Heyraud, et al. (1986) Evaluation of the protective effect of BCG vaccination by a case-control study in Yaounde, Cameroon. Tubercle 67 283-288.
315. O Tidjani, A Amendome and HG ten Dam (1986) The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle 67 269-281.
316. Gordin FM, Slutkin G, Schecter G, et al. Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings. Am Rev Respir Dis 139:1090–1093, 1989.
317. A Patel, F Schofield, V Siskind, et al. (1991) Case-control evaluation of a school-age BCG vaccination programme in subtropical Australia. Bull World Health Organ 69 425-433.
318. C Shapiro, N Cook, D Evans, et al. (1985) A case-control study of BCG and childhood tuberculosis in Cali, Colombia. Int J Epidemiol 14 441-446.
319. PG Smith (1987) Evaluating interventions against tropical diseases. Int J Epidemiol 16 159-166.
320. RL Sepulveda, C Parcha and RU Sorensen (1992) Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis 73 372-377.
321. N Thilothammal, PV Kirshnamurthy, DK Runyan, et al. (1996) Does BCG vaccine prevent tuberculous meningitis? Arch Dis Child 74 144-147.
322. LC Rodriques, VK Diwan and JG Wheeler (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22 1154-1158.
323. GA Colditz, CS Berkey, F Mosteller, et al. (1995) The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 29-35.
324. GA Colditz, TF Brewer, CS Berkey, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271 698-702.
325. JAC Sterne, LC Rodrigues and IN Guedes (1998) Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 2 200-207.
326. Joint Tuberculosis Committee of the British Thoracic Society (2000) Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 55 887-901.
327. Centers for Disease Control and Prevention (1996) The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Committee for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 45(RR-4), 1-18.
328. A Lotte, O Wasz-Hockert, N Poisson, et al. (1984) BCG complications: estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 21 107-193.
329. MS Victoria and BR Shah (1985) Bacillus Calmette-Guérin lymphadenitis: a case report and review of the literature. Pediatr Infect Dis J 4 295-296.
330. FM Turnbull, PB McIntyre, HM Achat, et al. (2002) National study of adverse reactions after vaccination with bacille Calmette-Guérin. Clin Infect Dis 34(4), 447-453.
331. MA Brewer, KM Edwards, PS Palmer and HP Hinson (1994) Bacille Calmette-Guérin immunization in normal healthy adults. J Infect Dis 170 476-479.
332. PEM Fine, JM Ponnighaus and N Maine (1989) The distribution and implications of BCG scars, with particular reference to a population in Northern Malawi. Bull World Health Organ 67 35-42.
333. A Lotte, O Wasz-Hockert, N Poisson, et al. (1988) Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc 63 47-59.
334. J Reynes, C Perez, I Lamaury, et al. (1989) Bacille Calmette-Guérin adenitis 30 years after immunization in a patient with AIDS [letter]. J Infect Dis 160 727.
335. M Gheorghiu (1978) Potency and suppurative adenitis in BCG vaccination. Dev Biol Stand 41 79-84.
336. GR Muzy de Souza, CC Sant'Anna, S. Lapane Silva Jr, et al. (1983) Intradermal BCG vaccination complications-analysis of 51 cases. Tubercle 64 23-27.
337. CG Helmick, AJ D'Souza and N Goddard (1986) An outbreak of severe BCG axillary lymphadenitis in Saint Lucia, 1982–83. West Indies Med J 35 12-17.
338. KN Praveen, MF Smikle, P Prabhakar, et al. (1990) Outbreak of bacillus Calmette-Guérin-associated lymphadenitis and abscesses in Jamaican children. Pediatr Infect Dis J 9 890-893.
339. KL O'Brien, AJ Ruff, MA Louis, et al. (1995) Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 95 414-418.
340. S Caglayan, O Yegin, K Kayean, et al. (1987) Is medical therapy effective for regional lymphadenitis following BCG vaccination? Am J Dis Child 141 1213-1214.
341. F Oguz, S Mujgan, G Alper, et al. (1992) Treatment of bacillus Calmette-Guérin-associated lymphadenitis. Pediatr Infect Dis J 11 887-888.
342. World Health Organization (1986) BCG Vaccination of the Newborn: Rationale and Guidelines for Country Programs Geneva: World Health Organization
343. SP Hanley, J Gumb and JT MacFarlane (1985) Comparison of erythromycin and isoniazid in treatment of adverse reactions to BCG vaccination. Br Med J (Clin Res Ed) 290 970.
344. PM Murphy, DL Mayers, NF Brock and KF Wagner (1989) Cure of bacille Calmette-Guérin vaccination abscess with erythromycin. Rev Infect Dis 11 335-337.
345. JT Power, IC Stewart and JD Ross (1984) Erythromycin in the management of troublesome BCG lesions. Br J Dis Chest 78 192-193.
346. JS Goraya and VS Virdi (2001) Treatment of Calmette-Guérin bacillus adenitis: a metaanalysis. Pediatr Infect Dis J 20 632-634.
347. L Kroger, M Korppi, E Brander, et al. (1995) Osteitis caused by bacillus Calmette-Guérin vaccination: a retrospective analysis of 222 cases. J Infect Dis 172 574-576.
348. S Bergdahl, M Fellander and B Robertson (1976) BCG osteomyelitis: experience in the Stockholm region over the years 1961–1974. J Bone Joint Surg Br 58 212-216.
349. H Vanicek (1988) Complications after initial BCG vaccination in a 5-year period in the East Bohemia region. Cesk Pediatr 43 23-26.
350. M Bottiger (1982) Osteitis and other complications caused by generalized BCGitis. Acta Paediatr Scand 71 471-478.
351. A Rouillon and H Waaler (1976) BCG vaccination and epidemiological situation: a decision making approach to the use of BCG. Adv Tuberc Res 19 64-126.
352. FK Pedersen, HC Engbaek, H Hertz and B Vergmann (1978) Fatal BCG infection in an immunocompetent girl. Acta Paediatr Scand 67 519-523.
353. CL Trevenen and RD Pagtakhan (1982) Disseminated tuberculoid lesions in infants following BCG. Can Med J 15 502-504.
354. A Lachaux, B Descos, A Mertani, et al. (1986) Infection generalisée a BCG d'evolution favorable chez un nourrisson de 3 mois sans deficit immunitaire reconnu. Arch Fr Pediatr 43 807-809.
355. M Tardieu, C Truffot-Pernot, JP Carriere, et al. (1988) Tuberculosis meningitis due to BCG in two previously healthy children. Lancet 1 440-441.
356. H Gormsen (1956) On the occurrence of epithelioid cell granulomas in the organs of BCG vaccinated human beings. Acta Pathol Microbiol Scand 39(Suppl 111), 117-120.
357. JL Casanova, S Blanche, JF Emile, et al. (1996) Idiopathic disseminated bacille Calmette-Guérin infection: a French national retrospective study. Pediatrics 98 774-778.
358. K Konno, FM Feldmann and W McDermott (1967) Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95 461-469.
359. R Von Kries, VP Grunert, U Kaletsch, et al. (2000) Prevention of childhood leukemia by BCG vaccination in newborns? A population-based case-control study in Lower Saxony, Germany. Pediatr Hematol Oncol 17 541-550.
360. KF Kolmel, JM Grange, B Krone, et al. (2005) Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41(1), 118-125.
361. B Gonzalez, S Moreno, R Burdach, et al. (1989) Clinical presentation of bacillus Calmette-Guérin infections in patients with immunodeficiency syndromes. Pediatr Infect Dis J 8 201-206.
362. Y Kobayashi, Y Komazawa, M Kobayshi, et al. (1984) Presumed BCG infection in a boy with chronic granulomatous disease. Clin Pediatr 23 586-589.
363. C Houde and P Dery (1988) Mycobacterium bovis sepsis in an infant with human immunodeficiency virus infection. Pediatr Infect Dis J 11 810-811.
364. S Sicevic (1972) Generalized BCG tuberculosis with fatal course in two sisters. Acta Paediatr Scand 61 178-184.
365. EA Talbot, MD Perkins, SFM Silva, et al. (1997) Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis 24 1139-1146.
366. E Jouanguy, F Altare, S Lamhamedi, et al. (1996) Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 335 1956-1961.
367. H Elloumi-Zghal, MR Barbouche, J Chemli, et al. (2002) Clinical and genetic heterogeneity of inherited autosomal recessive susceptibility to disseminated Mycobacterium bovis bacilli Calmette-Guérin infection. J Infect Dis 185 1468-1475.
368. C Armbruster, W Junker, N Vetter and G Jaksch (1990) Disseminated bacille Calmette-Guérin infection in an AIDS patient 30 years after BCG vaccination [letter]. J Infect Dis 162 1216.
369. J Ninane, A Grymonprez, G Burtonboy, et al. (1988) Disseminated BCG in HIV infection. Arch Dis Child 63 1268-1269.
370. Centers for Disease Control and Prevention (1985) Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. MMWR 34 227-228.
371. K Edwards and DS Kernodle (1996) Possible hazards of routine bacillus Calmette-Guérin immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 15 836-838.
372. RL Colebunders, L Izaley, M Musampu, et al. (1988) BCG vaccine abscesses are unrelated to HIV infection [letter]. JAMA 259 352.
373. M Carswell (1987) BCG immunization in the children of HIV-positive mothers. AIDS 1 258.
374. Dabis F, Lepage P, Nsengumuremyi F, et al. Infection par le virus V1HI et vaccination de routine de l'enfant: une etude cohorte à Kigali, Rwanda-surveillance des effets indésirables de la vaccination [abstr C29]. In: Proceedings of the Conference Internationale, Les Implications du SIDA pour la Mère et l'Enfant, Paris, 1989.
375. Lallemant-Le Coeur S, Cheynier D, Lallemant M, et al. Complications loco-régionales de la vaccination par le BCG chez des enfants nés de mères positive pour anti-HIV1: etude cas-témoins à Brazzaville [abstr WG03]. In: Proceedings of the Fifth International Conference on AIDS, Montreal, 1989. Ottawa, Canada, International Development Research Center, 1989, p 982.
376. P Thaithumyanon, U Thisyakorn, S Punnahitananda, et al. (2000) Safety and immunogenicity of bacillus Calmette-Guérin vaccine in children born to HIV-1 infected women. Southeast Asian J Trop Med Public Health 31 482-486.
377. A Van Rie, SA Madhi, JR Heera, et al. (2006) Gamma interferon production in response to Mycobacterium bovis BCG Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers. Clin Vaccine Immun 13 246-252.
378. M Besnard, S Sauvion, C Offredo, et al. (1993) Bacillus Calmette-Guérin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 12 993-997.
379. AC Hesseling, BJ Marais, RP Gie, et al. (2007) The risk of disseminated Bacille Callmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25(1), 14-18.
380. IB Palme, B Gudetta, H Degefu, et al. (2001) Risk factors for human immunodeficiency virus infection in Ethiopian children with tuberculosis. Pediatr Infect Dis J 20 1066-1072.
381. WJ Moss, CJ Clements and NA Halsey (2003) Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Org 81 61-70.
382. T Puthanakit, P Oberdorfer, S Punjaisee, et al. (2005) Immune reconstitution syndrome due to Bacillus Calmette-Guerin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 41(7), 1049-1052.
383. GK Siberry and S Tessema (2006) Immune reconstitution syndrome precipitated by Bacille Calmette-Guerin after initiation of antiretroviral therapy. Pediatr Infect Dis J 25(7), 249-648.
384. DF Hoft, C Leonardi, T Milligan, et al. (1999) Clinical reactogenicity of intradermal bacilli Calmette-Guérin vaccination. Clin Infect Dis 28 785-790.
385. MA Brewer, KM Edwards, PS Palmer and HP Hinson (1994) Bacilli Calmette-Guérin immunization in normal healthy adults. J Infect Dis 170 476-479.
386. HG ten Dam and KL Hitze (1980) Does BCG vaccination protect the newborn and young infants? Bull World Health Organ 58 37-41.
387. World Health Organization (2004) BCG vaccine. WHO position paper. Wkly Epidemiol Rec 79 27-38.
388. AA Ferreira, MM Bunn-Moreno, CC Sant'Anna, et al. (1996) BCG vaccination in low birth weight newborns: analysis of lymphocyte proliferation, Il-2 generation and intradermal reaction to PPD. Tuber Lung Dis 77 476-481.
389. S Thayyil-Sudhan, A Kumar, M Singh, et al. (1999) Safety and effectiveness of BCG vaccination in preterm babies. Arch Dis Child Fetal Neonatal Ed 81 F64-F66.
390. PD Hart (1967) Efficacy and applicability of mass BCG vaccination in tuberculosis control. Br Med J 1 587-592.
391. I Sutherland and VH Springett (1989) The effects of the scheme for BCG vaccination of school children in England and Wales and the consequences of discontinuing the scheme at various dates. J Epidemiol Community Health 43 15-24.
392. VH Springett and I Sutherland (1990) BCG vaccination of school children in England and Wales. Thorax 45 83-88.
393. United Kingdom Health Departments (1996) Immunisation Against Infectious Diseases London: Her Majesty's Stationery Office 1-290.
394. Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceudical Officer Changes to the BCG vaccination program. Online. Available at: http.//www.dh.gov.uk/assetRoot/04/11/81/35/04118135.pdf Accessed June 19, 2006
395. SSS Teo and DV Shingadia (2006) Does BCG have a role in tuberculosis control and prevention in the United Kingdom? Arch Dis Child 91 529-531.
396. OM Dantas, RA Ximenes, M.F. de Albuquerque MdeF, et al. (2006) A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int J Tuberc Lung Dis 10(5), 536-541.
397. V Romanus, A Svensson and HO Hallander (1992) The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989. Tuberc Lung Dis 73 150-161.
398. L Trnka, D Dankova and E Svandova (1993) Six years’ experience with the discontinuation of BCG vaccination. Tuberc Lung Dis 74 167-172.
399. International Union Against Tuberculosis and Lung Disease (1994) Criteria for discontinuation of vaccination programmes using Bacille Calmette Guérin (BCG) in countries with a low prevalence of tuberculosis. Tuber Lung Dis 75 179-181.
400. WHO Expert Committee on Leprosy Seventh Report WHO Tech Rep Ser No 874, 1998
401. World Health Organization (2001) BCG in immunization programmes. Wkly Epidemiol Rec 76 33-40.
402. J Noeske, C Kuaban, S Rondini, et al. (2004) Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 70 520-526.
403. F Portaels, J Aguiar, M Debacker, et al. (2001) Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 72:62–65, 2004.395. Brewer TF, Heymann SJ, Krumplitsch SM, et al. Strategies to decrease tuberculosis in US homeless populations: a computer simulation model. JAMA 286 834-842.
404. AC Hesseling, H Rabie, BJ Marais, et al. (2006) Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 42(4), 559-561.
405. WJ Moss, JC Clements and NA Halsey (2003) Immunization of children at risk of infection with human immunodeficiency virus. Bull WHO 81 61-71.
406. B Briggs, RS Illingworth and J Lorber (1956) The human source of tuberculous infection in children. Lancet 1 263-266.
407. RH Andrews, S Devadatta, W Fox, et al. (1963) Prevalence of tuberculosis among close family contacts of tuberculous patients in south India, and influence of segregation of the patient on the early attack rate. Bull World Health Organ 23 463-510.
408. CV Ramakrishnan, RH Andrews, S Devadatta, et al. (1964) Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in south India under domiciliary treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 25 361-407.
409. V Romanus (1987) Tuberculosis in bacillus Calmette-Guérin-immunized and unimmunized children in Sweden: a ten year evaluation following the cessation of general bacillus Calmette-Guérin immunization of the newborn in 1975. Pediatr Infect Dis J 6 272-280.
410. IM Orme (2006) Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24 2-19.
411. YAW Skeiky and JC Sadoff (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4(6), 469-476.
412. L Brandt, M Elhay, I Rosenkrands, et al. (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 791-795.
413. P Andersen (1994) Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62 2536-2544.
414. SL Baldwin, C D'Souza, AD Roberts, et al. (1998) Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66 2951-2959.
415. MA Horwitz, BW Lee, BJ Dillon and G Harth (1995) Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 92 1530-1534.
416. YA Skeiky, MR Alderson, PJ Ovendale, et al. (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 7618-7628.
417. AW Olsen, A Williams, LM Okkels, et al. (2004) Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 6148-6150.
418. J Dietrich, C Aagaard, R Leah, et al. (2005) Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174 6332-6339.
419. K Huygen (2005) Plasmid DNA vaccination. Microbes Infect 7 932-938.
420. I Cebere, L Dorrell, H McShane, et al. (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 417-425.
421. H McShane, AA Pathan, CR Sander, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 1240-1244.
422. H McShane, AA Pathan, CR Sander, et al. (2005) Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 47-52.
423. T Lang, AV Hill, H McShane, et al. (2005) New TB vaccine granted orphan drug status. BMJ 331 1476.
424. MK Hondalus, S Bardarov, R Russell, et al. (2000) Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 68 2888-2898.
425. SL Sampson, CC Dascher, VK Sambandamurthy, et al. (2004) Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 72 3031-3071.
426. RH Copenhaver, E Sepulveda, LY Armitige, et al. (2004) A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun 72 7084-7095.
427. R Pinto, BM Saunders, LR Camacho, et al. (2004) Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guerin vaccine. J Infect Dis 189 105-112.
428. KN Lewis, R Liao, KM Guinn, et al. (2003) Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis 187 117-123.
429. L Grode, P Seiler, S Baumann, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115 2472-2479.
430. MA Horwitz and G Harth (2003) A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71 1672-1679.
431. JV Brooks, AA Frank, MA Keen, et al. (2001) Boosting vaccine for tuberculosis. Infect Immun 69 2714-2717.
432. L Brandt, YA Skeiky, MR Alderson, et al. (2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 6622-6632.